Literature DB >> 18519721

Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.

Steven N Leonard1, Chrissy M Cheung, Michael J Rybak.   

Abstract

We evaluated the activity of ceftobiprole against 100 community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) and 100 hospital-associated MRSA (HA-MRSA) isolates. Eight isolates were evaluated by time-kill studies for kill rate and potential for synergy with tobramycin. Ceftobiprole MIC(50) and MIC(90) values were 1 and 2 microg/ml, respectively, against CA-MRSA and HA-MRSA. In time-kill analysis, ceftobiprole was bactericidal at all concentrations tested.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18519721      PMCID： PMC2493094          DOI： 10.1128/AAC.00257-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Authors:  Ronald N Jones; Lalitagauri M Deshpande; Alan H Mutnick; Douglas J Biedenbach
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus.

Authors:  Kunyan Zhang; Jo-Ann McClure; Sameer Elsayed; Thomas Louie; John M Conly
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

Authors:  Cesar A Arias; Kavindra V Singh; Diana Panesso; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

6.  Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

8.  A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.

Authors:  Gary J Noel; Karen Bush; Partha Bagchi; Juliana Ianus; Richard S Strauss
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

9.  Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus.

Authors:  Sharon J Peacock; Catrin E Moore; Anita Justice; Maria Kantzanou; Lisa Story; Kathryn Mackie; Gael O'Neill; Nicholas P J Day
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.

Authors:  L M Deshpande; R N Jones
Journal:  Clin Microbiol Infect       Date:  2003-11       Impact factor: 8.067
View more
  14 in total

1.  In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  C Germel; A Haag; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-09       Impact factor: 3.267

2.  Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Jamie Kisgen; Dana Whitney
Journal:  P T       Date:  2008-11

3.  Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  Azzam Saleh-Mghir; Oana Dumitrescu; Aurélien Dinh; Yassine Boutrad; Laurent Massias; Emilie Martin; François Vandenesch; Jérôme Etienne; Gérard Lina; Anne Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

Review 4.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jeffrey Fernandez; Darren Abbanat; Wenchi Shang; Wenping He; Karen Amsler; James Hastings; Anne Marie Queenan; John L Melton; Alfred M Barron; Robert K Flamm; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

6.  Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.

Authors:  David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

8.  In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.

Authors:  O Gallon; C Guillet-Caruba; B Lamy; F Laurent; F Doucet-Populaire; J-W Decousser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-06       Impact factor: 3.267

Review 9.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Authors:  Michael A Pfaller; Robert K Flamm; Rodrigo E Mendes; Jennifer M Streit; Jennifer I Smart; Kamal A Hamed; Leonard R Duncan; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.